Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

PURPOSE: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimization of screening techniques may reduce failure r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Kim N., Barnicle, Alan, Sibilla, Caroline, Lai, Zhongwu, Corcoran, Claire, Barrett, J. Carl, Adelman, Carrie A., Qiu, Ping, Easter, Ashley, Dearden, Simon, Oxnard, Geoffrey R., Agarwal, Neeraj, Azad, Arun, de Bono, Johann, Mateo, Joaquin, Olmos, David, Thiery-Vuillemin, Antoine, Harrington, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811161/
https://www.ncbi.nlm.nih.gov/pubmed/36043882
http://dx.doi.org/10.1158/1078-0432.CCR-22-0931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811161/
https://www.ncbi.nlm.nih.gov/pubmed/36043882
http://dx.doi.org/10.1158/1078-0432.CCR-22-0931

Ejemplares similares